<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Am J Hypertens</journal-id><journal-id journal-id-type="iso-abbrev">Am J Hypertens</journal-id><journal-id journal-id-type="pmc-domain-id">1976</journal-id><journal-id journal-id-type="pmc-domain">ajh</journal-id><journal-id journal-id-type="publisher-id">ajh</journal-id><journal-title-group><journal-title>American Journal of Hypertension</journal-title></journal-title-group><issn pub-type="ppub">0895-7061</issn><issn pub-type="epub">1941-7225</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11094384</article-id><article-id pub-id-type="pmcid-ver">PMC11094384.1</article-id><article-id pub-id-type="pmcaid">11094384</article-id><article-id pub-id-type="pmcaiid">11094384</article-id><article-id pub-id-type="pmid">38436491</article-id><article-id pub-id-type="doi">10.1093/ajh/hpae020</article-id><article-id pub-id-type="publisher-id">hpae020</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject><subj-group subj-group-type="category-toc-heading"><subject>Resistant Hypertension</subject></subj-group></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00200</subject><subject>AcademicSubjects/SCI00960</subject></subj-group></article-categories><title-group><article-title>Real-World Impact of Blood Pressure Control in Patients With Apparent Treatment-Resistant or Difficult-to-Control Hypertension and Stages 3 and 4 Chronic Kidney Disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Bakris</surname><given-names initials="G">George</given-names></name><aff>
<institution>University of Chicago Medicine</institution>, <addr-line>Chicago, Illinois</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="C">Cindy</given-names></name><aff>
<institution>Janssen Scientific Affairs, LLC</institution>, <addr-line>Titusville, New Jersey</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Campbell</surname><given-names initials="AK">Alicia K</given-names></name><aff>
<institution>Janssen Scientific Affairs, LLC</institution>, <addr-line>Titusville, New Jersey</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Ashton</surname><given-names initials="V">Veronica</given-names></name><aff>
<institution>Janssen Scientific Affairs, LLC</institution>, <addr-line>Titusville, New Jersey</addr-line>, <country country="US">USA</country></aff><xref rid="c1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Haskell</surname><given-names initials="L">Lloyd</given-names></name><aff>
<institution>Janssen Research &amp; Development, LLC</institution>, <addr-line>Raritan, New Jersey</addr-line>, <country country="US">USA</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Singhal</surname><given-names initials="M">Mukul</given-names></name><aff>
<institution>Janssen Scientific Affairs, LLC</institution>, <addr-line>Titusville, New Jersey</addr-line>, <country country="US">USA</country></aff></contrib></contrib-group><author-notes><corresp id="c1">Corresponding author: Veronica Ashton (<email>vashton1@its.jnj.com</email>).</corresp></author-notes><pub-date pub-type="collection"><month>6</month><year>2024</year></pub-date><pub-date pub-type="epub" iso-8601-date="2024-03-04"><day>04</day><month>3</month><year>2024</year></pub-date><volume>37</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">462379</issue-id><fpage>438</fpage><lpage>446</lpage><history><date date-type="received"><day>09</day><month>11</month><year>2023</year></date><date date-type="rev-recd"><day>02</day><month>2</month><year>2024</year></date><date date-type="accepted"><day>26</day><month>2</month><year>2024</year></date><date date-type="corrected-typeset"><day>21</day><month>3</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>04</day><month>03</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>16</day><month>05</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-16 00:25:13.853"><day>16</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024. Published by Oxford University Press on behalf of American Journal of Hypertension, Ltd.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="hpae020.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="hpae020.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>BACKGROUND</title><p>Chronic kidney disease (CKD) is a common comorbidity in patients with apparent treatment-resistant hypertension (aTRH). We assessed clinical outcomes, healthcare resource utilization events, and costs in patients with aTRH or difficult-to-control hypertension and stage 3&#8211;4 CKD with uncontrolled vs. controlled BP.</p></sec><sec id="s2"><title>METHODS</title><p>This retrospective cohort study used linked IQVIA Ambulatory EMR&#8211;US and IQVIA PharMetrics Plus claims databases. Adult patients had claims for &#8805;3 antihypertensive medication classes within 30 days between 01/01/2015 and 06/30/2021, 2 office BP measures recorded 1&#8211;90 days apart, &#8805;1 claim with ICD-9/10-CM diagnosis codes for CKD 3/4, and &#8805;1 year of continuous enrollment. Baseline BP was defined as uncontrolled (&#8805;130/80 mm Hg) or controlled (&lt;130/80 mm Hg) BP. Outcomes included risk of major adverse cardiovascular events plus (MACE+; stroke, myocardial infarction, heart failure hospitalization), end-stage renal disease (ESRD), healthcare resource utilization events, and costs during follow-up.</p></sec><sec id="s3"><title>RESULTS</title><p>Of 3,966 patients with stage 3&#8211;4 CKD using &#8805;3 antihypertensive medications, 2,479 had uncontrolled BP and 1,487 had controlled BP. After adjusting for baseline differences, patients with uncontrolled vs. controlled BP had a higher risk of MACE+ (HR [95% CI]: 1.18 [1.03&#8211;1.36]), ESRD (1.85 [1.44&#8211;2.39]), inpatient hospitalization (rate ratio [95% CI]: 1.35 [1.28&#8211;1.43]), and outpatient visits (1.12 [1.11&#8211;1.12]) and incurred higher total medical and pharmacy costs (mean difference [95% CI]: $10,055 [$6,741&#8211;$13,646] per patient per year).</p></sec><sec id="s4"><title>CONCLUSIONS</title><p>Patients with aTRH and stage 3&#8211;4 CKD and uncontrolled BP despite treatment with &#8805;3 antihypertensive classes had an increased risk of MACE+ and ESRD and incurred greater healthcare resource utilization and medical expenditures compared with patients taking &#8805;3 antihypertensive classes with controlled BP.</p></sec></abstract><kwd-group><kwd>blood pressure</kwd><kwd>blood pressure control</kwd><kwd>chronic kidney disease</kwd><kwd>health economics</kwd><kwd>hypertension</kwd><kwd>real-world analysis</kwd><kwd>treatment-resistant hypertension</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source><institution-wrap><institution>Janssen Scientific Affairs, LLC</institution><institution-id institution-id-type="DOI">10.13039/100017183</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><page-count count="9"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Hypertension is a leading contributor to preventable mortality worldwide and a major cause of cardiovascular and kidney disease, highlighting the need for improved blood pressure (BP) control strategies to reduce the associated burden on individuals and health services.<sup><xref rid="CIT0001" ref-type="bibr">1&#8211;3</xref></sup> For many patients, hypertension is adequately controlled with a regimen of up to 3 antihypertensive drugs. However, for some patients, BP remains above goal despite concurrent treatment with 3 antihypertensive medications of different classes, or they require 4 or more antihypertensives to achieve target BP. Such cases are termed apparent treatment-resistant hypertension (aTRH).<sup><xref rid="CIT0001" ref-type="bibr">1</xref>,<xref rid="CIT0004" ref-type="bibr">4</xref></sup> Pooled data from 2009 to 2014 showed that more than 10.3 million adults in the United States had aTRH according to the American College of Cardiology (ACC) and American Heart Association (AHA) 2017 guidelines definition of uncontrolled BP (systolic BP/diastolic BP &#8805;130/80 mm Hg).<sup><xref rid="CIT0004" ref-type="bibr">4</xref>,<xref rid="CIT0005" ref-type="bibr">5</xref></sup> When using the older definition of uncontrolled BP (&#8805;140/90 mm Hg), 9.2 million adults met the definition of aTRH.<sup><xref rid="CIT0005" ref-type="bibr">5</xref>,<xref rid="CIT0006" ref-type="bibr">6</xref></sup></p><p>Compared with individuals with nonresistant hypertension, patients with aTRH are at an increased risk for adverse clinical outcomes, have impairments in health-related quality of life, and have an increased risk of cardiovascular mortality.<sup><xref rid="CIT0004" ref-type="bibr">4</xref>,<xref rid="CIT0007" ref-type="bibr">7&#8211;10</xref></sup> There appears to be a close association between aTRH and the development and progression of chronic kidney disease (CKD).<sup><xref rid="CIT0011" ref-type="bibr">11</xref></sup> Almost 20% of patients with aTRH have CKD<sup><xref rid="CIT0012" ref-type="bibr">12</xref></sup> while, in patients with CKD, up to half meet the definition of aTRH.<sup><xref rid="CIT0013" ref-type="bibr">13</xref>,<xref rid="CIT0014" ref-type="bibr">14</xref></sup> In patients with CKD, the presence of aTRH is statistically significantly associated with an increased risk of renal events (adjusted hazard ratio [HR], 1.28; 95% confidence interval [CI]: 1.11, 1.46) and cardiovascular complications (i.e., myocardial infarction, stroke, peripheral artery disease, congestive heart failure [HF]; HR, 1.48; 95% CI: 1.28, 1.46).<sup><xref rid="CIT0013" ref-type="bibr">13</xref></sup> While the clinical burden of aTRH on patients with CKD has been documented, data evaluating healthcare and economic burden among patients with aTRH and comorbid CKD are limited. The objective of this analysis was to assess clinical outcomes, healthcare resource utilization events, and costs among patients with hypertension using &#8805;3 antihypertensive medication classes and stage 3/4 CKD, comparing those with uncontrolled vs. controlled BP.</p><sec sec-type="materials" id="s5"><title>METHODS</title><sec id="s6"><title>Data sources</title><p>The details of the data sources used in this study have been published previously.<sup><xref rid="CIT0015" ref-type="bibr">15</xref></sup> In brief, the study used linked data from 2 US-based databases: the IQVIA Ambulatory EMR&#8211;US database and the IQVIA adjudicated health plan claims (PharMetrics Plus) data. If a variable for the same patient was present in both databases, PharMetrics Plus was used as the primary source. These data were made available by IQVIA and used under license for the current study and are not publicly available. Other researchers should contact <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.iqvia.com" ext-link-type="uri">https://www.iqvia.com</ext-link>.</p></sec><sec id="s7"><title>Study design and patients</title><p>The design of this retrospective cohort study has been published previously (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1</xref> online).<sup><xref rid="CIT0015" ref-type="bibr">15</xref></sup> For the current analysis, eligible patients had to be &#8805;18 years of age, concurrently taking &#8805;3 antihypertensive medication classes within 30 days between 1 January 2015 and 30 June 2021, and have stage 3/4 CKD at baseline based on <italic toggle="yes">International Classification of Diseases, Ninth/Tenth Revision, Clinical Modification</italic> (ICD-9/10-CM) diagnosis codes. The index regimen date was defined as the date when the criterion for concurrent use of &#8805;3 antihypertensive medications was met. Patients were required to have 2 office-based BP measurements (on different dates &#8804;90 days apart) between 30 days and 11 months after the index regimen date, and the date of the second measurement was defined as the index date. Patients had to have &#8805;365 days of continuous health plan enrollment before the index date, which served as the baseline period.</p></sec><sec id="s8"><title>Definitions and assessments</title><p>Baseline systolic and diastolic BP were defined as the mean of the first 2 measurements recorded during office visits on different dates &#8804;90 days apart between 30 days and 11 months after the index regimen date, an approach consistent with clinical guidelines.<sup><xref rid="CIT0004" ref-type="bibr">4</xref></sup> In the primary analyses, uncontrolled BP was defined as &#8805;130/80 mm Hg, and controlled BP was defined as &lt;130/80 mm Hg, consistent with the 2017 and 2021 ACC/AHA guideline recommendations.<sup><xref rid="CIT0004" ref-type="bibr">4</xref>,<xref rid="CIT0016" ref-type="bibr">16</xref></sup> We also conducted a sensitivity analysis using the BP &lt;140/90 mm Hg goal as controlled BP and BP &#8805;140/90 mm Hg as uncontrolled BP per the 2020 International Society of Hypertension (ISH) guidelines and the Seventh Report of the Joint National Committee (JNC 7).<sup><xref rid="CIT0017" ref-type="bibr">17</xref>,<xref rid="CIT0018" ref-type="bibr">18</xref></sup></p><p>The composite major adverse cardiovascular events plus (MACE+) endpoint included hospitalization with a primary diagnosis of stroke, myocardial infarction, or HF during the follow-up period, while end-stage renal disease (ESRD) was defined as being on dialysis for &#8805;90 days or undergoing kidney transplantation during the follow-up period. Patients were followed until the earliest of the first MACE+ or ESRD event, end of health plan enrollment, or end of available data.</p><p>The following healthcare resource utilization events were assessed: hospitalizations and length of stay, emergency room visits, hospital outpatient visits, physician office visits, and pharmacy fills. Healthcare resource utilization costs were categorized as medical costs (hospitalization, emergency room visits, hospital outpatient visits, and primary care or specialist physician office visits), pharmacy costs (pharmacy fills), and overall healthcare costs (medical plus pharmacy costs).</p></sec><sec id="s9"><title>Ethics</title><p>Use of the IQVIA databases was reviewed by the New England Institutional Review Board (IRB) and was determined to be exempt from broad IRB approval, as this study was a retrospective database review that did not involve identified human participants. Confidentiality of patient records was maintained throughout the study. Study reports did not identify individual patients or physicians. The sponsor did not receive patient-identifying information during the study.</p></sec><sec id="s10"><title>Statistical analysis</title><p>Patient demographics and clinical characteristics were assessed using descriptive statistics, including means and SDs for continuous variables and relative frequencies and percentages for categorical variables. Between-group differences were assessed using standardized differences. A standardized difference &lt;10% was considered balanced. For clinical outcomes, incidence rates were calculated as the total number of cases during the follow-up over total follow-up time (years) and reported per 1,000 patient-years (PYs). Multivariable regression models were used for between-group comparisons. Conditional Cox proportional hazard models were used, adjusting for unbalanced covariates, and calculating the HR and corresponding 95% CI. Rates of healthcare resource utilization were calculated as the number of events divided by PYs of observation. Rate ratios (RRs) were used for between-group comparisons. Direct costs were calculated using mean cost per PY, which was calculated by dividing the costs incurred during the follow-up period by PYs of observation. All costs were inflated to 2021 US dollars based on the medical care component of the Consumer Price Index. A generalized linear model with gamma distribution was used to estimate the mean differences, 95% CIs, and <italic toggle="yes">P</italic> values. <italic toggle="yes">P</italic> values &lt;0.05 were considered statistically significant. All analyses were performed using the Instant Health Data Platform (Panalgo, LLC, Boston, MA) and SAS Enterprise 7.15 (SAS Institute, Cary, NC).</p></sec></sec><sec id="s11"><title>RESULTS</title><sec id="s12"><title>Patient disposition</title><p>Of the approximately 18 million patients who were present in both databases, 3,966 had an ICD-9/10-CM diagnosis code for stage 3/4 CKD and met all other inclusion criteria (<xref rid="F1" ref-type="fig">Figure 1</xref>). Of the 3,966 patients included in the analysis, 2,479 (62.5%) had uncontrolled BP and 1,487 (37.5%) had controlled BP according to the primary analysis definition of uncontrolled BP (&#8805;130/80 mm Hg), while 1,357 (34.2%) had uncontrolled BP and 2,609 (65.8%) had controlled BP according to the sensitivity analysis definition of uncontrolled BP (&#8805;140/90 mm Hg).</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p>Patient flowchart for IQVIA Ambulatory EMR&#8211;US and PharMetrics Plus linked claims. Abbreviations: anti-HTN, antihypertensive; BP, blood pressure; CKD, chronic kidney disease; ICD-9/10-CM, <italic toggle="yes">International Classification of Diseases, Ninth/Tenth Revision, Clinical Modification</italic>; SBP, systolic blood pressure.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="hpae020_fig1.jpg"/></fig></sec><sec id="s13"><title>Patient demographic and clinical characteristics during baseline period</title><p>There were imbalances (standardized differences &#8805;10%) in patient characteristics at baseline between those with uncontrolled and controlled BP (<xref rid="T1" ref-type="table">Tables 1</xref> and <xref rid="T2" ref-type="table">2</xref> and <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S1</xref> online). Patients with uncontrolled BP were younger than those with controlled BP (64.5 vs. 67.5 years), and there was a greater proportion of African American patients in the uncontrolled vs. controlled BP group (15.4% vs. 10.4%). Baseline comorbidities that were less frequently observed in patients with uncontrolled vs. controlled BP included congestive HF (34.1% vs. 42.9%), chronic pulmonary disease (30.5% vs. 38.5%), peripheral vascular disease (25.3% vs. 33.5%), atrial fibrillation (18.5% vs. 29.3%), and myocardial infarction (11.7% vs. 16.3%; <xref rid="T2" ref-type="table">Table 2</xref>). The mean number of antihypertensive medication classes taken at baseline was higher in the uncontrolled vs. controlled BP group (3.4 vs. 3.3; <xref rid="T1" ref-type="table">Table 1</xref>). There were no statistically significant differences between the uncontrolled and controlled BP groups in baseline healthcare resource utilization events or costs (<xref rid="T2" ref-type="table">Table 2</xref>).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1.</label><caption><p>Patient baseline demographic characteristics and antihypertensive medication use (primary analysis population)</p></caption><table frame="hsides" rules="groups" width="100%" border="1"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Uncontrolled BP<break/>(<italic toggle="yes">n</italic>&#8197;=&#8197;2,479)</th><th align="center" rowspan="1" colspan="1">Controlled BP<break/>(<italic toggle="yes">n</italic>&#8197;=&#8197;1,487)</th><th align="center" rowspan="1" colspan="1">Standardized difference,<xref rid="T1Fn2" ref-type="table-fn"><sup>a</sup></xref> %</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Age, y, mean (SD)</td><td align="center" rowspan="1" colspan="1">64.5 (13.1)</td><td align="center" rowspan="1" colspan="1">67.5 (13.4)</td><td align="center" rowspan="1" colspan="1">22.5</td></tr><tr><td align="center" colspan="4" rowspan="1">Age group, y, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;18&#8211;44</td><td align="center" rowspan="1" colspan="1">170 (6.9)</td><td align="center" rowspan="1" colspan="1">82 (5.5)</td><td align="center" rowspan="1" colspan="1">5.6</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;45&#8211;64</td><td align="center" rowspan="1" colspan="1">1,162 (46.9)</td><td align="center" rowspan="1" colspan="1">538 (36.2)</td><td align="center" rowspan="1" colspan="1">21.8</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;65&#8211;74</td><td align="center" rowspan="1" colspan="1">559 (225)</td><td align="center" rowspan="1" colspan="1">372 (25.0)</td><td align="center" rowspan="1" colspan="1">5.8</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;75&#8211;79</td><td align="center" rowspan="1" colspan="1">246 (9.9)</td><td align="center" rowspan="1" colspan="1">184 (12.4)</td><td align="center" rowspan="1" colspan="1">7.8</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;&#8805;80</td><td align="center" rowspan="1" colspan="1">342 (13.8)</td><td align="center" rowspan="1" colspan="1">311 (20.9)</td><td align="center" rowspan="1" colspan="1">18.9</td></tr><tr><td align="center" rowspan="1" colspan="1">Men, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1">1,398 (56.4)</td><td align="center" rowspan="1" colspan="1">811 (54.5)</td><td align="center" rowspan="1" colspan="1">3.7</td></tr><tr><td align="center" colspan="4" rowspan="1">Race, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;White</td><td align="center" rowspan="1" colspan="1">1,631 (65.8)</td><td align="center" rowspan="1" colspan="1">1,069 (71.9)</td><td align="center" rowspan="1" colspan="1">13.2</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Black or African American</td><td align="center" rowspan="1" colspan="1">382 (15.4)</td><td align="center" rowspan="1" colspan="1">154 (10.4)</td><td align="center" rowspan="1" colspan="1">15.1</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Asian</td><td align="center" rowspan="1" colspan="1">95 (3.8)</td><td align="center" rowspan="1" colspan="1">72 (4.8)</td><td align="center" rowspan="1" colspan="1">5.0</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Other</td><td align="center" rowspan="1" colspan="1">48 (1.9)</td><td align="center" rowspan="1" colspan="1">27 (1.8)</td><td align="center" rowspan="1" colspan="1">0.9</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Unknown</td><td align="center" rowspan="1" colspan="1">319 (12.9)</td><td align="center" rowspan="1" colspan="1">162 (10.9)</td><td align="center" rowspan="1" colspan="1">6.1</td></tr><tr><td align="center" colspan="4" rowspan="1">Insurance type, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Commercial</td><td align="center" rowspan="1" colspan="1">1,099 (44.3)</td><td align="center" rowspan="1" colspan="1">569 (38.3)</td><td align="center" rowspan="1" colspan="1">12.3</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Medicare<xref rid="T1Fn3" ref-type="table-fn"><sup>b</sup></xref></td><td align="center" rowspan="1" colspan="1">607 (24.5)</td><td align="center" rowspan="1" colspan="1">494 (33.2)</td><td align="center" rowspan="1" colspan="1">19.4</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Self-insured</td><td align="center" rowspan="1" colspan="1">655 (26.4)</td><td align="center" rowspan="1" colspan="1">362 (24.3)</td><td align="center" rowspan="1" colspan="1">4.8</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Medicaid</td><td align="center" rowspan="1" colspan="1">117 (4.7)</td><td align="center" rowspan="1" colspan="1">62 (4.2)</td><td align="center" rowspan="1" colspan="1">2.7</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Unknown/missing</td><td align="center" rowspan="1" colspan="1">1 (0.04)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2.8</td></tr><tr><td align="center" colspan="4" rowspan="1">US Census region, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;South</td><td align="center" rowspan="1" colspan="1">1,176 (47.4)</td><td align="center" rowspan="1" colspan="1">617 (41.5)</td><td align="center" rowspan="1" colspan="1">12.0</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Midwest</td><td align="center" rowspan="1" colspan="1">503 (20.3)</td><td align="center" rowspan="1" colspan="1">380 (25.6)</td><td align="center" rowspan="1" colspan="1">12.5</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Northeast</td><td align="center" rowspan="1" colspan="1">371 (15.0)</td><td align="center" rowspan="1" colspan="1">218 (14.7)</td><td align="center" rowspan="1" colspan="1">0.9</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;West</td><td align="center" rowspan="1" colspan="1">427 (17.2)</td><td align="center" rowspan="1" colspan="1">270 (18.2)</td><td align="center" rowspan="1" colspan="1">2.4</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Unknown</td><td align="center" rowspan="1" colspan="1">2 (0.1)</td><td align="center" rowspan="1" colspan="1">2 (0.1)</td><td align="center" rowspan="1" colspan="1">1.6</td></tr><tr><td align="center" colspan="4" rowspan="1">Number of antihypertensive medication classes<xref rid="T1Fn4" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Mean (SD)</td><td align="center" rowspan="1" colspan="1">3.4 (0.7)</td><td align="center" rowspan="1" colspan="1">3.3 (0.6)</td><td align="center" rowspan="1" colspan="1">20.8</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;3, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1">1,670 (67.4)</td><td align="center" rowspan="1" colspan="1">1,138 (76.5)</td><td align="center" rowspan="1" colspan="1">20.5</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;4, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1">623 (25.1)</td><td align="center" rowspan="1" colspan="1">283 (19.0)</td><td align="center" rowspan="1" colspan="1">14.7</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;&#8805;5, <italic toggle="yes">n</italic> (%)</td><td align="center" rowspan="1" colspan="1">186 (7.5)</td><td align="center" rowspan="1" colspan="1">66 (4.4)</td><td align="center" rowspan="1" colspan="1">13.0</td></tr></tbody></table><table-wrap-foot><fn id="T1Fn1"><p>Abbreviation: BP, blood pressure.</p></fn><fn id="T1Fn2"><p>
<sup>a</sup>Standardized difference with values &#8805;10% considered statistically significant.</p></fn><fn id="T1Fn3"><p>
<sup>b</sup>Medicare Part C, Medicare Advantage, and Medicare Supplemental Plans.</p></fn><fn id="T1Fn4"><p>
<sup>c</sup>Eleven antihypertensive medication classes were included in the study: diuretics (including loop diuretics, thiazide diuretics, potassium-sparing diuretics, and mineralocorticoid receptor antagonists), beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, alpha blockers, alpha-2 receptor agonists, combined alpha and beta blockers, central agonists, peripheral adrenergic inhibitors, and vasodilators.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2.</label><caption><p>Patient baseline clinical characteristics, comorbid conditions, and healthcare resource utilization costs (primary analysis population)</p></caption><table frame="hsides" rules="groups" width="100%" border="1"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Uncontrolled BP<break/>(<italic toggle="yes">n</italic>&#8197;=&#8197;2,479)</th><th align="center" rowspan="1" colspan="1">Controlled BP<break/>(<italic toggle="yes">n</italic>&#8197;=&#8197;1,487)</th><th align="center" rowspan="1" colspan="1">Standardized difference,<xref rid="T2Fn2" ref-type="table-fn"><sup>a</sup></xref> %</th></tr></thead><tbody><tr><td align="center" colspan="4" rowspan="1">SBP<xref rid="T2Fn3" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Mean (SD)</td><td align="center" rowspan="1" colspan="1">143.8 (14.4)</td><td align="center" rowspan="1" colspan="1">118.2 (8.2)</td><td align="center" rowspan="1" colspan="1">218.8</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Median (IQR)</td><td align="center" rowspan="1" colspan="1">140.5 (17.5)</td><td align="center" rowspan="1" colspan="1">120.0 (10.0)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1">DBP<xref rid="T2Fn3" ref-type="table-fn"><sup>b</sup></xref></td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Mean (SD)</td><td align="center" rowspan="1" colspan="1">79.0 (10.1)</td><td align="center" rowspan="1" colspan="1">68.2 (7.2)</td><td align="center" rowspan="1" colspan="1">123.3</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Median (IQR)</td><td align="center" rowspan="1" colspan="1">79.6 (13.0)</td><td align="center" rowspan="1" colspan="1">69.0 (10.5)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" colspan="4" rowspan="1">QCI score</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Mean (SD)</td><td align="center" rowspan="1" colspan="1">3.3 (2.2)</td><td align="center" rowspan="1" colspan="1">3.7 (2.4)</td><td align="center" rowspan="1" colspan="1">13.9</td></tr><tr><td align="center" colspan="4" rowspan="1">Comorbidities &#8805;10%, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Hyperlipidemia</td><td align="center" rowspan="1" colspan="1">2,106 (85.0)</td><td align="center" rowspan="1" colspan="1">1,293 (87.0)</td><td align="center" rowspan="1" colspan="1">5.8</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Type 2 diabetes mellitus</td><td align="center" rowspan="1" colspan="1">1,590 (64.1)</td><td align="center" rowspan="1" colspan="1">887 (59.7)</td><td align="center" rowspan="1" colspan="1">9.3</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Anemia</td><td align="center" rowspan="1" colspan="1">1,272 (51.3)</td><td align="center" rowspan="1" colspan="1">727 (48.9)</td><td align="center" rowspan="1" colspan="1">4.8</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Congestive heart failure</td><td align="center" rowspan="1" colspan="1">846 (34.1)</td><td align="center" rowspan="1" colspan="1">638 (42.9)</td><td align="center" rowspan="1" colspan="1">18.1</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Chronic pulmonary disease</td><td align="center" rowspan="1" colspan="1">755 (30.5)</td><td align="center" rowspan="1" colspan="1">573 (38.5)</td><td align="center" rowspan="1" colspan="1">17.1</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Peripheral vascular disease</td><td align="center" rowspan="1" colspan="1">628 (25.3)</td><td align="center" rowspan="1" colspan="1">498 (33.5)</td><td align="center" rowspan="1" colspan="1">18.0</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Atrial fibrillation</td><td align="center" rowspan="1" colspan="1">458 (18.5)</td><td align="center" rowspan="1" colspan="1">436 (29.3)</td><td align="center" rowspan="1" colspan="1">25.6</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Cerebrovascular disease</td><td align="center" rowspan="1" colspan="1">540 (21.8)</td><td align="center" rowspan="1" colspan="1">364 (24.5)</td><td align="center" rowspan="1" colspan="1">6.4</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Depression</td><td align="center" rowspan="1" colspan="1">509 (20.5)</td><td align="center" rowspan="1" colspan="1">355 (23.9)</td><td align="center" rowspan="1" colspan="1">8.0</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Osteoarthritis</td><td align="center" rowspan="1" colspan="1">457 (18.4)</td><td align="center" rowspan="1" colspan="1">289 (19.4)</td><td align="center" rowspan="1" colspan="1">2.6</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Anxiety</td><td align="center" rowspan="1" colspan="1">445 (18.0)</td><td align="center" rowspan="1" colspan="1">285 (19.2)</td><td align="center" rowspan="1" colspan="1">3.1</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Any malignancy<xref rid="T2Fn4" ref-type="table-fn"><sup>c</sup></xref></td><td align="center" rowspan="1" colspan="1">409 (16.5)</td><td align="center" rowspan="1" colspan="1">254 (17.1)</td><td align="center" rowspan="1" colspan="1">1.6</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;MI</td><td align="center" rowspan="1" colspan="1">290 (11.7)</td><td align="center" rowspan="1" colspan="1">242 (16.3)</td><td align="center" rowspan="1" colspan="1">13.2</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Mild liver disease</td><td align="center" rowspan="1" colspan="1">223 (9.0)</td><td align="center" rowspan="1" colspan="1">165 (11.1)</td><td align="center" rowspan="1" colspan="1">7.0</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Stroke</td><td align="center" rowspan="1" colspan="1">240 (9.7)</td><td align="center" rowspan="1" colspan="1">155 (10.4)</td><td align="center" rowspan="1" colspan="1">2.5</td></tr><tr><td align="center" colspan="4" rowspan="1">Possible causes of secondary hypertension, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Sleep apnea</td><td align="center" rowspan="1" colspan="1">661 (26.7)</td><td align="center" rowspan="1" colspan="1">363 (24.4)</td><td align="center" rowspan="1" colspan="1">5.2</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Alcohol use disorder</td><td align="center" rowspan="1" colspan="1">105 (4.2)</td><td align="center" rowspan="1" colspan="1">56 (3.8)</td><td align="center" rowspan="1" colspan="1">2.4</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Renal artery stenosis</td><td align="center" rowspan="1" colspan="1">37 (1.5)</td><td align="center" rowspan="1" colspan="1">14 (0.9)</td><td align="center" rowspan="1" colspan="1">5.0</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Hyperaldosteronism</td><td align="center" rowspan="1" colspan="1">13 (0.5)</td><td align="center" rowspan="1" colspan="1">5 (0.3)</td><td align="center" rowspan="1" colspan="1">2.9</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Cushing syndrome</td><td align="center" rowspan="1" colspan="1">2 (0.1)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">4.0</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Specific diagnosis code for secondary hypertension</td><td align="center" rowspan="1" colspan="1">71 (2.9)</td><td align="center" rowspan="1" colspan="1">22 (1.5)</td><td align="center" rowspan="1" colspan="1">9.5</td></tr><tr><td align="center" colspan="4" rowspan="1">BMI, kg/m<sup>2</sup></td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Mean (SD)</td><td align="center" rowspan="1" colspan="1">33.3 (8.5)</td><td align="center" rowspan="1" colspan="1">31.7 (8.3)</td><td align="center" rowspan="1" colspan="1">19.2</td></tr><tr><td align="center" colspan="4" rowspan="1">Smoking status, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Smoker</td><td align="center" rowspan="1" colspan="1">811 (32.7)</td><td align="center" rowspan="1" colspan="1">535 (36.0)</td><td align="center" rowspan="1" colspan="1">6.9</td></tr><tr><td align="center" colspan="4" rowspan="1">Patients with &#8805;1 healthcare resource utilization event, <italic toggle="yes">n</italic> (%)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Inpatient hospitalization</td><td align="center" rowspan="1" colspan="1">1,133 (45.7)</td><td align="center" rowspan="1" colspan="1">700 (47.1)</td><td align="center" rowspan="1" colspan="1">2.7</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;ER visit</td><td align="center" rowspan="1" colspan="1">727 (29.3)</td><td align="center" rowspan="1" colspan="1">464 (31.2)</td><td align="center" rowspan="1" colspan="1">4.1</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Hospital outpatient visit</td><td align="center" rowspan="1" colspan="1">2,385 (96.2)</td><td align="center" rowspan="1" colspan="1">1,435 (96.5)</td><td align="center" rowspan="1" colspan="1">1.6</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Physician office visit</td><td align="center" rowspan="1" colspan="1">2,369 (95.6)</td><td align="center" rowspan="1" colspan="1">1,416 (95.2)</td><td align="center" rowspan="1" colspan="1">1.6</td></tr><tr><td align="center" colspan="4" rowspan="1">Number of events PPPY, mean (SD)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Inpatient hospitalization</td><td align="center" rowspan="1" colspan="1">1.1 (3.7)</td><td align="center" rowspan="1" colspan="1">1.1 (1.9)</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;ER visit</td><td align="center" rowspan="1" colspan="1">0.5 (1.4)</td><td align="center" rowspan="1" colspan="1">0.6 (1.2)</td><td align="center" rowspan="1" colspan="1">1.6</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Hospital outpatient visit</td><td align="center" rowspan="1" colspan="1">71.8 (82.0)</td><td align="center" rowspan="1" colspan="1">72.8 (81.0)</td><td align="center" rowspan="1" colspan="1">1.3</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Physician office visit</td><td align="center" rowspan="1" colspan="1">13.2 (10.2)</td><td align="center" rowspan="1" colspan="1">13.8 (10.7)</td><td align="center" rowspan="1" colspan="1">5.5</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Pharmacy fill</td><td align="center" rowspan="1" colspan="1">31.4 (22.4)</td><td align="center" rowspan="1" colspan="1">33.3 (23.5)</td><td align="center" rowspan="1" colspan="1">8.3</td></tr><tr><td align="center" colspan="4" rowspan="1">Length of hospital stay, days, mean (SD)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;All patients</td><td align="center" rowspan="1" colspan="1">6.6 (16.1)</td><td align="center" rowspan="1" colspan="1">7.9 (28.2)</td><td align="center" rowspan="1" colspan="1">6.0</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Patients with &#8805;1 hospitalization</td><td align="center" rowspan="1" colspan="1">14.4 (21.4)</td><td align="center" rowspan="1" colspan="1">16.9 (39.2)</td><td align="center" rowspan="1" colspan="1">7.9</td></tr><tr><td align="center" rowspan="1" colspan="1">Total medical cost PPPY, USD, mean (SD)</td><td align="center" rowspan="1" colspan="1">30,959 (56,946)</td><td align="center" rowspan="1" colspan="1">33,750 (62,107)</td><td align="center" rowspan="1" colspan="1">4.7</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Inpatient hospitalization</td><td align="center" rowspan="1" colspan="1">17,463 (42,242)</td><td align="center" rowspan="1" colspan="1">20,444 (52,303)</td><td align="center" rowspan="1" colspan="1">6.3</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;ER visit</td><td align="center" rowspan="1" colspan="1">545 (2,002)</td><td align="center" rowspan="1" colspan="1">503 (1,687)</td><td align="center" rowspan="1" colspan="1">2.2</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Hospital outpatient visit</td><td align="center" rowspan="1" colspan="1">11,454 (26,901)</td><td align="center" rowspan="1" colspan="1">11,216 (22,441)</td><td align="center" rowspan="1" colspan="1">1.0</td></tr><tr><td align="center" rowspan="1" colspan="1">&#8195;Physician office visit</td><td align="center" rowspan="1" colspan="1">1,359 (1,140)</td><td align="center" rowspan="1" colspan="1">1,376 (1,246)</td><td align="center" rowspan="1" colspan="1">1.4</td></tr><tr><td align="center" rowspan="1" colspan="1">Total pharmacy cost PPPY, USD, mean (SD)</td><td align="center" rowspan="1" colspan="1">6,276 (17,131)</td><td align="center" rowspan="1" colspan="1">6,344 (15,326)</td><td align="center" rowspan="1" colspan="1">0.4</td></tr><tr><td align="center" rowspan="1" colspan="1">Total cost (medical and pharmacy) PPPY, USD, mean (SD)</td><td align="center" rowspan="1" colspan="1">37,235 (60,739)</td><td align="center" rowspan="1" colspan="1">40,094 (64,517)</td><td align="center" rowspan="1" colspan="1">4.6</td></tr></tbody></table><table-wrap-foot><fn id="T2Fn1"><p>Abbreviations: BMI, body mass index; BP, blood pressure; DBP, diastolic blood pressure; ER, emergency room; IQR, interquartile range; MI, myocardial infarction; PPPY, per patient per year; QCI, Quan-Charlson Comorbidity Index; SBP, systolic blood pressure; USD, United States dollars.</p></fn><fn id="T2Fn2"><p>
<sup>a</sup>Standardized difference with values &#8805;10% considered statistically significant.</p></fn><fn id="T2Fn3"><p>
<sup>b</sup>Based on the mean of measurements obtained during 2 office visits on separate days 1&#8211;90 days apart.</p></fn><fn id="T2Fn4"><p>
<sup>c</sup>Includes lymphoma and leukemia; excludes malignant neoplasm of the skin.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s14"><title>Clinical outcomes</title><p>For MACE+, mean (SD) follow-up time was 2.2 (1.9) years in the uncontrolled BP group and 2.3 (2.0) years in the controlled BP group, while follow-up times for ESRD were 2.3 (2.0) and 2.6 (2.1) years, respectively. The unadjusted rate of the MACE+ composite outcome was 97.3 per 1,000 PY in the uncontrolled BP group and 101.8 per 1,000 PY in the controlled BP group; rates of the individual MACE+ components are shown in <xref rid="T3" ref-type="table">Table 3</xref>. The unadjusted rate of ESRD was notably higher in the uncontrolled BP group (48.2 per 1,000 PY) compared with the controlled BP group (23.1 per 1,000 PY). After adjusting for baseline differences in demographic and clinical characteristics, compared with patients with controlled BP, patients with uncontrolled BP were at an increased risk of developing MACE+ (HR, 1.18; 95% CI: 1.03, 1.36) and ESRD (HR, 1.85; 95% CI: 1.44, 2.39; <xref rid="F2" ref-type="fig">Figure 2</xref>). MACE+ risk was mainly driven by an increased risk of stroke (HR, 1.35; 95% CI: 1.05, 1.74) and HF hospitalization (HR, 1.20; 95% CI: 1.02, 1.42).</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3.</label><caption><p>Unadjusted incidence of clinical outcomes (primary analysis population)</p></caption><table frame="hsides" rules="groups" width="100%" border="1"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1"/><th align="center" colspan="2" rowspan="1">Uncontrolled BP (<italic toggle="yes">n</italic>&#8197;=&#8197;2,479)</th><th align="center" colspan="2" rowspan="1">Controlled BP (<italic toggle="yes">n</italic>&#8197;=&#8197;1,487)</th></tr><tr><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">n</italic> (%)</th><th align="center" rowspan="1" colspan="1">Incidence (95% CI)<xref rid="T3Fn2" ref-type="table-fn"><sup>a</sup></xref></th><th align="center" rowspan="1" colspan="1">
<italic toggle="yes">n</italic> (%)</th><th align="center" rowspan="1" colspan="1">Incidence (95% CI)<xref rid="T3Fn2" ref-type="table-fn"><sup>a</sup></xref></th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">MACE+</td><td align="center" rowspan="1" colspan="1">539 (21.7)</td><td align="center" rowspan="1" colspan="1">97.3 (89.8, 105.5)</td><td align="center" rowspan="1" colspan="1">348 (23.4)</td><td align="center" rowspan="1" colspan="1">101.8 (92.1, 112.4)</td></tr><tr><td align="center" rowspan="1" colspan="1">Stroke</td><td align="center" rowspan="1" colspan="1">174 (7.0)</td><td align="center" rowspan="1" colspan="1">28.3 (24.5, 32.8)</td><td align="center" rowspan="1" colspan="1">101 (6.8)</td><td align="center" rowspan="1" colspan="1">26.2 (21.6, 31.8)</td></tr><tr><td align="center" rowspan="1" colspan="1">MI</td><td align="center" rowspan="1" colspan="1">137 (5.5)</td><td align="center" rowspan="1" colspan="1">22.0 (18.7, 26.0)</td><td align="center" rowspan="1" colspan="1">100 (6.7)</td><td align="center" rowspan="1" colspan="1">26.2 (21.6, 31.8)</td></tr><tr><td align="center" rowspan="1" colspan="1">HF hospitalization</td><td align="center" rowspan="1" colspan="1">388 (15.7)</td><td align="center" rowspan="1" colspan="1">66.9 (60.7, 73.6)</td><td align="center" rowspan="1" colspan="1">252 (16.9)</td><td align="center" rowspan="1" colspan="1">70.2 (62.3, 79.1)</td></tr><tr><td align="center" rowspan="1" colspan="1">ESRD</td><td align="center" rowspan="1" colspan="1">278 (11.2)</td><td align="center" rowspan="1" colspan="1">48.2 (43.0, 54.1)</td><td align="center" rowspan="1" colspan="1">88 (5.9)</td><td align="center" rowspan="1" colspan="1">23.1 (18.8, 28.4)</td></tr></tbody></table><table-wrap-foot><fn id="T3Fn1"><p>Abbreviations: BP, blood pressure; CI, confidence interval; ESRD, end-stage renal disease; HF, heart failure; MACE+, major adverse cardiovascular events plus; MI, myocardial infarction.</p></fn><fn id="T3Fn2"><p>
<sup>a</sup>Number is per 1,000 person-years at risk.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><p>Adjusted clinical outcomes (primary analysis population). (Controlled BP is the reference group. Model was adjusted for age group, race, insurance type, US Census region, baseline comorbidities [Quan-Charlson Comorbidity Index score, congestive heart failure, myocardial infarction, peripheral vascular disease, chronic pulmonary disease, diabetes with chronic complications, atrial fibrillation], BMI category, use of antiplatelets, oral anticoagulants, antiarrhythmic drugs, and antidepressants, and number of index regimen drugs.) Abbreviations: BMI, body mass index; BP, blood pressure; CI, confidence interval; ESRD, end-stage renal disease; HR, hazard ratio; MACE+, major adverse cardiovascular events plus; MI, myocardial infarction.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="hpae020_fig2.jpg"/></fig></sec><sec id="s15"><title>Healthcare resource use and costs</title><p>In the primary analysis, patients in the uncontrolled BP group were more likely to have inpatient hospitalizations (adjusted RR, 1.35; 95% CI: 1.28, 1.43) and outpatient visits (adjusted RR, 1.12; 95% CI: 1.11, 1.12) compared with the controlled BP group, while the adjusted RR for emergency room visits was 0.95 (95% CI: 0.88, 1.03; <xref rid="F3" ref-type="fig">Figure 3</xref>). Mean (SD) length of hospital stay among patients with &#8805;1 hospitalization was 31.84 (59.12) days in patients with uncontrolled BP and 29.09 (43.08) days in those with controlled BP. Adjusted RR for pharmacy fills was 0.98 (95% CI: 0.97, 0.99) for the uncontrolled vs. controlled BP group. Patients in the uncontrolled vs. controlled BP group incurred higher mean total medical costs (adjusted cost difference per patient per year, +$9,638) and mean total pharmacy costs (+$325), resulting in a total additional cost of $10,055 for patients with uncontrolled vs. controlled BP (<xref rid="F4" ref-type="fig">Figure 4</xref>). Total medical costs were driven primarily by outpatient visits (+$6,514) and inpatient hospital admissions (+$3,202). Number of healthcare resource utilization events and mean costs, along with unadjusted RRs for healthcare resource utilization events and costs, are shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Table S2</xref> online.</p><fig position="float" id="F3" orientation="portrait"><label>Figure 3.</label><caption><p>Adjusted healthcare resource utilization events (primary analysis population). (Controlled BP is the reference group. Model was adjusted for age group, race, insurance type, US Census region, baseline comorbidities [Quan-Charlson Comorbidity Index score, congestive heart failure, myocardial infarction, peripheral vascular disease, chronic pulmonary disease, diabetes with chronic complications, atrial fibrillation], BMI category, use of antiplatelets, oral anticoagulants, antiarrhythmic drugs, and antidepressants, and number of index regimen drugs.) <sup>&#8224;</sup>Outpatient visits include hospital outpatient, physician office, and skilled nursing facility visits. Abbreviations: BMI, body mass index; BP, blood pressure; CI, confidence interval; ER, emergency room; RR, rate ratio.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="hpae020_fig3.jpg"/></fig><fig position="float" id="F4" orientation="portrait"><label>Figure 4.</label><caption><p>Healthcare resource utilization costs in patients with uncontrolled vs. controlled BP (primary analysis population). (Adjusted healthcare resource utilization cost differences are shown as adjusted estimate [95% CI] using controlled BP as the reference group. Model was adjusted for age group, race, insurance type, US Census region, baseline comorbidities [Quan-Charlson Comorbidity Index score, congestive HF, myocardial infarction, peripheral vascular disease, chronic pulmonary disease, diabetes with chronic complications, atrial fibrillation], BMI category, use of antiplatelets, oral anticoagulants, antiarrhythmic drugs, and antidepressants, and number of index regimen drugs.) <sup>&#8224;</sup><italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.05. <sup>&#8225;</sup>Outpatient visits include hospital outpatient, physician office, and skilled nursing facility visits. Abbreviations: BMI, body mass index; BP, blood pressure; CI, confidence interval; ER, emergency room; HF, heart failure; PPPY, per patient per year; USD, United States dollars.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="hpae020_fig4.jpg"/></fig></sec><sec id="s16"><title>Sensitivity analysis</title><p>In the sensitivity analysis using BP &#8805;140/90 mm Hg, imbalances in demographics and comorbidities between the uncontrolled and controlled BP groups at baseline were consistent with those in the primary analyses (<xref rid="sup1" ref-type="supplementary-material">Supplementary Tables S3</xref> and <xref rid="sup1" ref-type="supplementary-material">S4</xref> online).</p><p>Overall, the results for clinical outcomes, healthcare resource utilization events, and costs in the sensitivity analysis were consistent with the primary analysis. In the sensitivity analysis population, mean (SD) follow-up times for MACE+ and ESRD were 2.2 (1.9) and 2.3 (2.0) years, respectively, in the uncontrolled BP group and 2.3 (2.0) and 2.5 (2.1) years, respectively, in the controlled BP group. Unadjusted proportion (rate) of the MACE+ composite outcome was 23.4% (107.8 per 1,000 PY) in the uncontrolled BP group and 21.8% (94.7 per 1,000 PY) in the controlled BP group (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table S5</xref> online). The unadjusted proportion and rate of ESRD were higher in the uncontrolled BP group (13.3%, 59.3 per 1,000 PY) compared with the controlled BP group (7.1%, 28.4 per 1,000 PY). After adjusting for baseline differences in demographic and clinical characteristics, patients in the uncontrolled BP group were at a 31% and 82% increased risk of developing MACE+ and ESRD compared with the controlled BP group; increased risk of all MACE+ components was seen in the uncontrolled vs. controlled BP group (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S2</xref> online). In the sensitivity analysis, patients in the uncontrolled BP group were 26% more likely to have inpatient hospitalizations and 18% more likely to have outpatient visits compared with the controlled BP group, while the adjusted RR for emergency room visits was 1.04 (95% CI: 0.95, 1.13; <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S3</xref> online). Compared with the controlled BP group, the uncontrolled BP group had higher costs for inpatient hospitalizations and outpatient visits, resulting in a $9,073 higher total cost (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S4</xref> online).</p></sec></sec><sec id="s17"><title>DISCUSSION</title><p>In this retrospective cohort study, we used the IQVIA Ambulatory EMR&#8211;US and PharMetrics Plus claims databases to evaluate the healthcare resource utilization burden along with the risk of MACE+ and ESRD in patients with aTRH or difficult-to-control hypertension and stage 3/4 CKD. We found that among CKD stage 3/4 patients, those with hypertension who were using 3 or more antihypertensive treatments but still had uncontrolled BP incurred greater healthcare resource utilization and medical expenditures and had an increased risk of developing MACE+ and ESRD than those with controlled hypertension.</p><p>Using the definition of uncontrolled BP in our primary analysis (&#8805;130/80 mm Hg), we found an increase in inpatient hospitalizations (HR, 1.35), an increase in outpatient visits (HR, 1.12), and an increase of approximately $10,000 in total medical and pharmacy costs in patients with uncontrolled BP compared with controlled BP, adjusted for differences in baseline demographic and clinical characteristics. Similarly, in our sensitivity analysis using a BP threshold of &#8805;140/90 mm Hg, there were increases in inpatient hospitalizations (HR, 1.26) and outpatient visits (HR, 1.18), and total costs increased by approximately $9,000. Thus, our results confirm the healthcare and economic burden of uncontrolled aTRH in patients with stage 3/4 CKD.</p><p>aTRH is known to place a burden on healthcare services in terms of resource use and cost. Consistent with our results, in a US population cohort study involving 4,650 participants with hypertension, those with aTRH and uncontrolled BP had a greater mean number of primary care visits (2.77 vs. 2.27 per year; <italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.001), cardiologist visits (0.50 vs. 0.35 per year; <italic toggle="yes">P</italic>&#8197;=&#8197;0.014), and nephrology visits (0.24 vs. 0.07 per year; <italic toggle="yes">P</italic>&#8197;&lt;&#8197;0.001) than those without aTRH. Participants with controlled aTRH had fewer visits compared with those with uncontrolled BP, although the differences were not statistically significant.<sup><xref rid="CIT0019" ref-type="bibr">19</xref></sup></p><p>Overall, hypertension is one of the top 10 highest health expenditures in the United States, costing an estimated $79 billion in 2016.<sup><xref rid="CIT0020" ref-type="bibr">20</xref></sup> The presence of comorbidities adds to the economic burden of hypertension. Data from the 2011&#8211;2014 Medical Expenditure Panel Survey estimated mean annual costs of hypertension ranging from $3,914 per patient for those with no comorbidities to $13,920 for those with &#8805;3 comorbidities; in particular, the presence of comorbid kidney disease increased annual medical expenditure to $14,248 per patient compared with $9,274 for hypertensive patients without kidney disease.<sup><xref rid="CIT0021" ref-type="bibr">21</xref></sup> Our results add further evidence of the economic burden of aTRH for patients with kidney disease.</p><p>In this analysis, patients in the uncontrolled BP cohort were younger and had a lower incidence of comorbidities (e.g., congestive HF, atrial fibrillation, peripheral vascular disease, chronic pulmonary disease) at baseline compared with patients in the controlled BP cohort, who represent a sicker population. The more controlled BP in this sicker population may be related to more frequent physician visits and better adherence related to management of comorbidities. After adjusting for differences in baseline demographic and clinical characteristics between the uncontrolled and controlled BP groups in the primary analysis, patients with uncontrolled BP (&#8805;130/80 mm Hg) had an 18% increased risk of MACE+ and an 85% increase in ESRD while, in the sensitivity analysis, patients with uncontrolled BP (&#8805;140/90 mm Hg) had a 31% increased risk of MACE+ and an 82% increase in ESRD. Thus, while the absolute number of patients meeting the uncontrolled BP criterion of the sensitivity analysis was reduced relative to the primary analysis, the risk for MACE+ was higher. The greater risk of MACE+ in the sensitivity analysis is consistent with previous findings that elevated BP is associated with higher risk of MACE+<sup><xref rid="CIT0022" ref-type="bibr">22&#8211;24</xref></sup> and confirms these findings in a population of patients with stage 3/4 CKD.</p><p>The increase in ESRD risk in patients with uncontrolled BP compared with controlled BP was similarly high in the primary and sensitivity analyses after adjusting for baseline differences in demographic and clinical characteristics. Our findings are consistent with previous studies showing increased risk of ESRD with elevated BP, even at more stringent BP thresholds.<sup><xref rid="CIT0010" ref-type="bibr">10</xref>,<xref rid="CIT0025" ref-type="bibr">25&#8211;27</xref></sup> For example, in a US cohort study of 316,675 participants without kidney disease at baseline, those with BP of 120&#8211;129/80&#8211;84 mm Hg had a statistically significant increased risk of 62% for developing ESRD compared with those with BP &lt;120/80 mm Hg, with the magnitude of risk increasing for higher BP categories.<sup><xref rid="CIT0026" ref-type="bibr">26</xref></sup> Likewise, in our study population with stage 3/4 CKD, an increased risk for progression of kidney disease to ESRD was evident at the more stringent threshold for uncontrolled BP of &#8805;130/80 mm Hg in the primary analysis. The results of this study reinforce the potential for earlier and more stringent BP control in reducing the risk of ESRD, particularly in patients with existing kidney disease.</p><p>Our findings of increased risk of adverse clinical outcomes in patients with CKD and uncontrolled vs. controlled BP are consistent with those of previous studies. In an analysis of 3,367 patients with CKD enrolled in the Chronic Renal Insufficiency Cohort study, those with aTRH had a 38% higher risk of the composite endpoint of myocardial infarction, stroke, peripheral arterial disease, congestive HF, and all-cause mortality, and a 28% increased risk of renal events, compared with patients without aTRH.<sup><xref rid="CIT0013" ref-type="bibr">13</xref></sup> Likewise, in a prospective study involving 436 patients with CKD, aTRH was associated with a 24% higher risk of cardiovascular events and 2.7-fold higher risk of renal events.<sup><xref rid="CIT0028" ref-type="bibr">28</xref></sup></p><p>There are limitations to this study associated with the analysis of administrative claims data. The data used in this study were limited by the information recorded and translated into structured data elements and may not be generalizable to the entire US population. The results, however, were derived from a large population-based sample of patients with treated hypertension and CKD that reflects current real-world practice. Errors in BP measurement may have resulted in the inaccurate classification of uncontrolled or controlled BP. In addition, patients with stage 3/4 CKD were identified using ICD-9/10-CM codes and not laboratory data, so patients from this group may have been underreported and patients with a low estimated glomerular filtration rate and/or proteinuria may have been missed. Claims data are prone to coding errors and inconsistencies; while statistical methods were used to balance patient groups, the potential for residual confounding could not be eliminated. Claims for medications do not indicate that medications were taken as prescribed. Medication adherence and the prescription of clinically appropriate dosages are important factors in aTRH; neither was assessed in this study. Furthermore, there is overlap in drug classes used to treat hypertension and HF, and the study did not assess whether all medications were prescribed for hypertension or another indication.</p><p>Among patients with stage 3/4 CKD, those with uncontrolled aTRH had an increased risk of developing MACE+ and ESRD and incurred greater healthcare resource utilization and medical expenditures than those with controlled hypertension who used 3 or more antihypertensive classes. Controlling BP may subsequently reduce healthcare resource utilization and economic burden in patients with aTRH and stage 3/4 CKD.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sup1" position="float" content-type="local-data" orientation="portrait"><label>hpae020_suppl_Supplementary_Figures_S1-S4_Tables_1-S5</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="hpae020_suppl_supplementary_figures_s1-s4_tables_1-s5.docx" position="float" orientation="portrait"/></supplementary-material></sec></body><back><sec id="s19"><title>FUNDING</title><p>This study was funded by Janssen Scientific Affairs, LLC. Statistical programming for this manuscript was performed by Kalla Sun, PhD, of TechData Service Company, LLC. Medical writing support was provided by Michelle Hughes, BSc (Hons), of Lumanity Communications Inc. and was funded by Janssen Scientific Affairs, LLC.</p></sec><sec id="s20"><title>AUTHOR CONTRIBUTIONS</title><p>All authors: conceptualization, investigation, methodology, writing, and visualization. C.C.: data curation, formal analysis, and software. M.S. and C.C.: project administration and validation. V.A. and M.S.: funding acquisition and supervision.</p></sec><sec sec-type="COI-statement" id="s21"><title>CONFLICT OF INTEREST</title><p>G.B. is supported by T32 NIH grant DK07011 and is a consultant to Bayer, KBP Biosciences, Ionis, Alnylam, AstraZeneca, Quantum Genomics, Janssen, Novo Nordisk, DiaMedica Therapeutics, and inRegen. C.C., A.K.C., V.A., and M.S. are employees of Janssen Scientific Affairs, LLC, and are Johnson &amp; Johnson stockholders. L.H. is an employee of Janssen Research &amp; Development, LLC, and is a Johnson &amp; Johnson stockholder.</p></sec><sec sec-type="data-availability" id="s22"><title>DATA AVAILABILITY</title><p>The data sharing policy of Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.janssen.com/clinical-trials/transparency" ext-link-type="uri">https://www.janssen.com/clinical-trials/transparency</ext-link>. These data were made available by IQVIA and used under license for the current study and are not publicly available. Other researchers should contact <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.iqvia.com" ext-link-type="uri">https://www.iqvia.com</ext-link>.</p></sec><ref-list id="r1"><title>REFERENCES</title><ref id="CIT0001"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carey</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Calhoun</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Bakris</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Brook</surname><given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Daugherty</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Dennison-Himmelfarb</surname><given-names>CR</given-names></string-name>, <string-name name-style="western"><surname>Egan</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Flack</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Gidding</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Judd</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Lackland</surname><given-names>DT</given-names></string-name>, <string-name name-style="western"><surname>Laffer</surname><given-names>CL</given-names></string-name>, <string-name name-style="western"><surname>Newton-Cheh</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Taler</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Textor</surname><given-names>SC</given-names></string-name>, <string-name name-style="western"><surname>Turan</surname><given-names>TN</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>WB</given-names></string-name></person-group>; <collab>American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council</collab>. <article-title>Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association</article-title>. <source>Hypertension</source><year>2018</year>; <volume>72</volume>:<fpage>e53</fpage>&#8211;<lpage>e90</lpage>.<pub-id pub-id-type="pmid">30354828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/HYP.0000000000000084</pub-id><pub-id pub-id-type="pmcid">PMC6530990</pub-id></mixed-citation></ref><ref id="CIT0002"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Forouzanfar</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Roth</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Ng</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Biryukov</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Marczak</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Alexander</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Estep</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Hassen Abate</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Akinyemiju</surname><given-names>TF</given-names></string-name>, <string-name name-style="western"><surname>Ali</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Alvis-Guzman</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Azzopardi</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Banerjee</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>B&#228;rnighausen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Basu</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Bekele</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Bennett</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Biadgilign</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Catal&#225;-L&#243;pez</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Feigin</surname><given-names>VL</given-names></string-name>, <string-name name-style="western"><surname>Fernandes</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Fischer</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Gebru</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Gona</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Gupta</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Hankey</surname><given-names>GJ</given-names></string-name>, <string-name name-style="western"><surname>Jonas</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Judd</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Khang</surname><given-names>YH</given-names></string-name>, <string-name name-style="western"><surname>Khosravi</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>YJ</given-names></string-name>, <string-name name-style="western"><surname>Kimokoti</surname><given-names>RW</given-names></string-name>, <string-name name-style="western"><surname>Kokubo</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Kolte</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Lopez</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Lotufo</surname><given-names>PA</given-names></string-name>, <string-name name-style="western"><surname>Malekzadeh</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Melaku</surname><given-names>YA</given-names></string-name>, <string-name name-style="western"><surname>Mensah</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Misganaw</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Mokdad</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Moran</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Nawaz</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Neal</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Ngalesoni</surname><given-names>FN</given-names></string-name>, <string-name name-style="western"><surname>Ohkubo</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Pourmalek</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Rafay</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Rai</surname><given-names>RK</given-names></string-name>, <string-name name-style="western"><surname>Rojas-Rueda</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Sampson</surname><given-names>UK</given-names></string-name>, <string-name name-style="western"><surname>Santos</surname><given-names>IS</given-names></string-name>, <string-name name-style="western"><surname>Sawhney</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Schutte</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Sepanlou</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Shifa</surname><given-names>GT</given-names></string-name>, <string-name name-style="western"><surname>Shiue</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Tedla</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Thrift</surname><given-names>AG</given-names></string-name>, <string-name name-style="western"><surname>Tonelli</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Truelsen</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Tsilimparis</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Ukwaja</surname><given-names>KN</given-names></string-name>, <string-name name-style="western"><surname>Uthman</surname><given-names>OA</given-names></string-name>, <string-name name-style="western"><surname>Vasankari</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Venketasubramanian</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Vlassov</surname><given-names>VV</given-names></string-name>, <string-name name-style="western"><surname>Vos</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Westerman</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Yan</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Yano</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Yonemoto</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Zaki</surname><given-names>MES</given-names></string-name>, <string-name name-style="western"><surname>Murray</surname><given-names>CJL.</given-names></string-name></person-group><article-title>Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990&#8211;2015</article-title>. <source>JAMA</source><year>2017</year>; <volume>317</volume>:<fpage>165</fpage>&#8211;<lpage>182</lpage>.<pub-id pub-id-type="pmid">28097354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2016.19043</pub-id></mixed-citation></ref><ref id="CIT0003"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mills</surname><given-names>KT</given-names></string-name>, <string-name name-style="western"><surname>Xu</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Bundy</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Kelly</surname><given-names>TN</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>He</surname><given-names>J.</given-names></string-name></person-group><article-title>A systematic analysis of worldwide population-based data on the global burden of chronic kidney disease in 2010</article-title>. <source>Kidney Int</source><year>2015</year>; <volume>88</volume>:<fpage>950</fpage>&#8211;<lpage>957</lpage>.<pub-id pub-id-type="pmid">26221752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ki.2015.230</pub-id><pub-id pub-id-type="pmcid">PMC4653075</pub-id></mixed-citation></ref><ref id="CIT0004"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Whelton</surname><given-names>PK</given-names></string-name>, <string-name name-style="western"><surname>Carey</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Aronow</surname><given-names>WS</given-names></string-name>, <string-name name-style="western"><surname>Casey</surname><given-names>DE</given-names><suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Collins</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Dennison Himmelfarb</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>DePalma</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Gidding</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Jamerson</surname><given-names>KA</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>MacLaughlin</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Muntner</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Ovbiagele</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>SC</given-names><suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Spencer</surname><given-names>CC</given-names></string-name>, <string-name name-style="western"><surname>Stafford</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Taler</surname><given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>KAS</given-names></string-name>, <string-name name-style="western"><surname>Williamson</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></string-name></person-group>. <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines</article-title>. <source>J Am Coll Cardiol</source><year>2018</year>; <volume>71</volume>:<fpage>e127</fpage>&#8211;<lpage>e248</lpage>.<pub-id pub-id-type="pmid">29146535</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2017.11.006</pub-id></mixed-citation></ref><ref id="CIT0005"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carey</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Sakhuja</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Calhoun</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Whelton</surname><given-names>PK</given-names></string-name>, <string-name name-style="western"><surname>Muntner</surname><given-names>P.</given-names></string-name></person-group><article-title>Prevalence of apparent treatment-resistant hypertension in the United States</article-title>. <source>Hypertension</source><year>2019</year>; <volume>73</volume>:<fpage>424</fpage>&#8211;<lpage>431</lpage>.<pub-id pub-id-type="pmid">30580690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/HYPERTENSIONAHA.118.12191</pub-id><pub-id pub-id-type="pmcid">PMC6693520</pub-id></mixed-citation></ref><ref id="CIT0006"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Weber</surname><given-names>MA</given-names></string-name>, <string-name name-style="western"><surname>Schiffrin</surname><given-names>EL</given-names></string-name>, <string-name name-style="western"><surname>White</surname><given-names>WB</given-names></string-name>, <string-name name-style="western"><surname>Mann</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Lindholm</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Kenerson</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Flack</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Carter</surname><given-names>BL</given-names></string-name>, <string-name name-style="western"><surname>Materson</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Ram</surname><given-names>CV</given-names></string-name>, <string-name name-style="western"><surname>Cohen</surname><given-names>DL</given-names></string-name>, <string-name name-style="western"><surname>Cadet</surname><given-names>JC</given-names></string-name>, <string-name name-style="western"><surname>Jean-Charles</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Taler</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Kountz</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Townsend</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Chalmers</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ramirez</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Bakris</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Schutte</surname><given-names>AE</given-names></string-name>, <string-name name-style="western"><surname>Bisognano</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Touyz</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Sica</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Harrap</surname><given-names>SB.</given-names></string-name></person-group><article-title>Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension</article-title>. <source>J Clin Hypertens (Greenwich)</source><year>2014</year>; <volume>16</volume>:<fpage>14</fpage>&#8211;<lpage>26</lpage>.<pub-id pub-id-type="pmid">24341872</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jch.12237</pub-id><pub-id pub-id-type="pmcid">PMC8031779</pub-id></mixed-citation></ref><ref id="CIT0007"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Carris</surname><given-names>NW</given-names></string-name>, <string-name name-style="western"><surname>Ghushchyan</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Libby</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>SM.</given-names></string-name></person-group><article-title>Health-related quality of life in persons with apparent treatment-resistant hypertension on at least four antihypertensives</article-title>. <source>J Hum Hypertens</source><year>2016</year>; <volume>30</volume>:<fpage>191</fpage>&#8211;<lpage>196</lpage>.<pub-id pub-id-type="pmid">26084656</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/jhh.2015.61</pub-id></mixed-citation></ref><ref id="CIT0008"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Daugherty</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Powers</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Magid</surname><given-names>DJ</given-names></string-name>, <string-name name-style="western"><surname>Tavel</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Masoudi</surname><given-names>FA</given-names></string-name>, <string-name name-style="western"><surname>Margolis</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>O&#8217;Connor</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Selby</surname><given-names>JV</given-names></string-name>, <string-name name-style="western"><surname>Ho</surname><given-names>PM.</given-names></string-name></person-group><article-title>Incidence and prognosis of resistant hypertension in hypertensive patients</article-title>. <source>Circulation</source><year>2012</year>; <volume>125</volume>:<fpage>1635</fpage>&#8211;<lpage>1642</lpage>.<pub-id pub-id-type="pmid">22379110</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.111.068064</pub-id><pub-id pub-id-type="pmcid">PMC3343635</pub-id></mixed-citation></ref><ref id="CIT0009"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kaczmarski</surname><given-names>KR</given-names></string-name>, <string-name name-style="western"><surname>Sozio</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Shafi</surname><given-names>T.</given-names></string-name></person-group><article-title>Resistant hypertension and cardiovascular disease mortality in the US: results from the National Health and Nutrition Examination Survey (NHANES)</article-title>. <source>BMC Nephrol</source><year>2019</year>; <volume>20</volume>:<fpage>138</fpage>.<pub-id pub-id-type="pmid">31023262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12882-019-1315-0</pub-id><pub-id pub-id-type="pmcid">PMC6485047</pub-id></mixed-citation></ref><ref id="CIT0010"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sim</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Bhandari</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Shi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Reynolds</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Calhoun</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Kalantar-Zadeh</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Jacobsen</surname><given-names>SJ.</given-names></string-name></person-group><article-title>Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension</article-title>. <source>Kidney Int</source><year>2015</year>; <volume>88</volume>:<fpage>622</fpage>&#8211;<lpage>632</lpage>.<pub-id pub-id-type="pmid">25945406</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ki.2015.142</pub-id><pub-id pub-id-type="pmcid">PMC4556588</pub-id></mixed-citation></ref><ref id="CIT0011"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Wolley</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Stowasser</surname><given-names>M.</given-names></string-name></person-group><article-title>Resistant hypertension and chronic kidney disease: a dangerous liaison</article-title>. <source>Curr Hypertens Rep</source><year>2016</year>; <volume>18</volume>:<fpage>36</fpage>.<pub-id pub-id-type="pmid">27072829</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11906-016-0641-x</pub-id></mixed-citation></ref><ref id="CIT0012"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>An</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Sim</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Calhoun</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Wei</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Zhou</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Luong</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Reynolds</surname><given-names>K.</given-names></string-name></person-group><article-title>Apparent treatment-resistant hypertension: characteristics and prevalence in a real-world environment of an integrated health system</article-title>. <source>J Hypertens</source><year>2020</year>; <volume>38</volume>:<fpage>1603</fpage>&#8211;<lpage>1611</lpage>.<pub-id pub-id-type="pmid">32251197</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/HJH.0000000000002419</pub-id></mixed-citation></ref><ref id="CIT0013"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Thomas</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Xie</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>HY</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Appel</surname><given-names>LJ</given-names></string-name>, <string-name name-style="western"><surname>Bodana</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Brecklin</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Drawz</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Flack</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Miller</surname><given-names>ER</given-names><suffix>III</suffix></string-name>, <string-name name-style="western"><surname>Steigerwalt</surname><given-names>SP</given-names></string-name>, <string-name name-style="western"><surname>Townsend</surname><given-names>RR</given-names></string-name>, <string-name name-style="western"><surname>Weir</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Rahman</surname><given-names>M</given-names></string-name></person-group>; <collab>CRIC Study Investigators</collab>. <article-title>Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: report from the Chronic Renal Insufficiency Cohort study</article-title>. <source>Hypertension</source><year>2016</year>; <volume>67</volume>:<fpage>387</fpage>&#8211;<lpage>396</lpage>.<pub-id pub-id-type="pmid">26711738</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/HYPERTENSIONAHA.115.06487</pub-id><pub-id pub-id-type="pmcid">PMC4713320</pub-id></mixed-citation></ref><ref id="CIT0014"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>An</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kurella Tamura</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Odden</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Ni</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Thomas</surname><given-names>IC</given-names></string-name>, <string-name name-style="western"><surname>Montez-Rath</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Sim</surname><given-names>JJ.</given-names></string-name></person-group><article-title>Prevalence of apparent treatment-resistant hypertension in chronic kidney disease in two large US health care systems</article-title>. <source>Clin J Am Soc Nephrol</source><year>2022</year>; <volume>17</volume>:<fpage>1457</fpage>&#8211;<lpage>1466</lpage>.<pub-id pub-id-type="pmid">36400564</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2215/CJN.04110422</pub-id><pub-id pub-id-type="pmcid">PMC9528269</pub-id></mixed-citation></ref><ref id="CIT0015"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bakris</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Campbell</surname><given-names>AK</given-names></string-name>, <string-name name-style="western"><surname>Ashton</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Haskell</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Singhal</surname><given-names>M.</given-names></string-name></person-group><article-title>Association of uncontrolled blood pressure in apparent treatment-resistant hypertension with increased risk of major adverse cardiovascular events plus</article-title>. <source>J Clin Hypertens (Greenwich)</source><year>2023</year>; <volume>25</volume>:<fpage>737</fpage>&#8211;<lpage>747</lpage>.<pub-id pub-id-type="pmid">37461262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jch.14701</pub-id><pub-id pub-id-type="pmcid">PMC10423765</pub-id></mixed-citation></ref><ref id="CIT0016"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jones</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Whelton</surname><given-names>PK</given-names></string-name>, <string-name name-style="western"><surname>Allen</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Clark</surname><given-names>D</given-names><suffix>III</suffix></string-name>, <string-name name-style="western"><surname>Gidding</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Muntner</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Nesbitt</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Mitchell</surname><given-names>NS</given-names></string-name>, <string-name name-style="western"><surname>Townsend</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Falkner</surname><given-names>B.</given-names></string-name></person-group><article-title>Management of stage 1 hypertension in adults with a low 10-year risk for cardiovascular disease: filling a guidance gap: a scientific statement from the American Heart Association</article-title>. <source>Hypertension</source><year>2021</year>; <volume>77</volume>:<fpage>e58</fpage>&#8211;<lpage>e67</lpage>.<pub-id pub-id-type="pmid">33910363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/HYP.0000000000000195</pub-id></mixed-citation></ref><ref id="CIT0017"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Unger</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Borghi</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Charchar</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Khan</surname><given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>Poulter</surname><given-names>NR</given-names></string-name>, <string-name name-style="western"><surname>Prabhakaran</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Ramirez</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Schlaich</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Stergiou</surname><given-names>GS</given-names></string-name>, <string-name name-style="western"><surname>Tomaszewski</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wainford</surname><given-names>RD</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Schutte</surname><given-names>AE.</given-names></string-name></person-group><article-title>2020 International Society of Hypertension Global Hypertension Practice Guidelines</article-title>. <source>Hypertension</source><year>2020</year>; <volume>75</volume>:<fpage>1334</fpage>&#8211;<lpage>1357</lpage>.<pub-id pub-id-type="pmid">32370572</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/HYPERTENSIONAHA.120.15026</pub-id></mixed-citation></ref><ref id="CIT0018"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chobanian</surname><given-names>AV</given-names></string-name>, <string-name name-style="western"><surname>Bakris</surname><given-names>GL</given-names></string-name>, <string-name name-style="western"><surname>Black</surname><given-names>HR</given-names></string-name>, <string-name name-style="western"><surname>Cushman</surname><given-names>WC</given-names></string-name>, <string-name name-style="western"><surname>Green</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Izzo</surname><given-names>JL</given-names><suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>DW</given-names></string-name>, <string-name name-style="western"><surname>Materson</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Oparil</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></string-name>, <string-name name-style="western"><surname>Roccella</surname><given-names>EJ</given-names></string-name></person-group>; <collab>Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee</collab>. <article-title>Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure</article-title>. <source>Hypertension</source><year>2003</year>; <volume>42</volume>:<fpage>1206</fpage>&#8211;<lpage>1252</lpage>.<pub-id pub-id-type="pmid">14656957</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.HYP.0000107251.49515.c2</pub-id></mixed-citation></ref><ref id="CIT0019"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Vemulapalli</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Deng</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Patel</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Kilgore</surname><given-names>ML</given-names></string-name>, <string-name name-style="western"><surname>Jones</surname><given-names>WS</given-names></string-name>, <string-name name-style="western"><surname>Curtis</surname><given-names>LH</given-names></string-name>, <string-name name-style="western"><surname>Irvin</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Svetkey</surname><given-names>LP</given-names></string-name>, <string-name name-style="western"><surname>Shimbo</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Calhoun</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Muntner</surname><given-names>P.</given-names></string-name></person-group><article-title>National patterns in intensity and frequency of outpatient care for apparent treatment-resistant hypertension</article-title>. <source>Am Heart J</source><year>2017</year>; <volume>186</volume>:<fpage>29</fpage>&#8211;<lpage>39</lpage>.<pub-id pub-id-type="pmid">28454830</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ahj.2017.01.008</pub-id><pub-id pub-id-type="pmcid">PMC8218938</pub-id></mixed-citation></ref><ref id="CIT0020"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dieleman</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Chapin</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Chen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>Z</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Horst</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Kaldjian</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Matyasz</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Scott</surname><given-names>KW</given-names></string-name>, <string-name name-style="western"><surname>Bui</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Campbell</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Duber</surname><given-names>HC</given-names></string-name>, <string-name name-style="western"><surname>Dunn</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Flaxman</surname><given-names>AD</given-names></string-name>, <string-name name-style="western"><surname>Fitzmaurice</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Naghavi</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Sadat</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Shieh</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Squires</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Yeung</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Murray</surname><given-names>CJL.</given-names></string-name></person-group><article-title>US health care spending by payer and health condition, 1996&#8211;2016</article-title>. <source>JAMA</source><year>2020</year>; <volume>323</volume>:<fpage>863</fpage>&#8211;<lpage>884</lpage>.<pub-id pub-id-type="pmid">32125402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.0734</pub-id><pub-id pub-id-type="pmcid">PMC7054840</pub-id></mixed-citation></ref><ref id="CIT0021"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Park</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Fang</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hawkins</surname><given-names>NA</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>G.</given-names></string-name></person-group><article-title>Comorbidity status and annual total medical expenditures in U.S. hypertensive adults</article-title>. <source>Am J Prev Med</source><year>2017</year>; <volume>53</volume>:<fpage>S172</fpage>&#8211;<lpage>S181</lpage>.<pub-id pub-id-type="pmid">29153118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amepre.2017.07.014</pub-id><pub-id pub-id-type="pmcid">PMC5836318</pub-id></mixed-citation></ref><ref id="CIT0022"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kim</surname><given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Kwon</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Shin</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Jung</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>DH</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>WH</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>IJ</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>HY</given-names></string-name>, <string-name name-style="western"><surname>Chung</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Ihm</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>KI</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Sohn</surname><given-names>IS</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>HC</given-names></string-name>, <string-name name-style="western"><surname>Shin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Ryu</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Pyun</surname><given-names>WB</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Sung</surname><given-names>KC.</given-names></string-name></person-group><article-title>Blood pressure levels and cardiovascular risk according to age in patients with diabetes mellitus: a nationwide population-based cohort study</article-title>. <source>Cardiovasc Diabetol</source><year>2020</year>; <volume>19</volume>:<fpage>181</fpage>.<pub-id pub-id-type="pmid">33076934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12933-020-01156-8</pub-id><pub-id pub-id-type="pmcid">PMC7574489</pub-id></mixed-citation></ref><ref id="CIT0023"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kwon</surname><given-names>CH</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Shin</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>CJ</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>HC</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Jung</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>DH</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>HL</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>HM</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>IJ</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>HY</given-names></string-name>, <string-name name-style="western"><surname>Chung</surname><given-names>WJ</given-names></string-name>, <string-name name-style="western"><surname>Ihm</surname><given-names>SH</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>KI</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>EJ</given-names></string-name>, <string-name name-style="western"><surname>Sohn</surname><given-names>IS</given-names></string-name>, <string-name name-style="western"><surname>Park</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shin</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ryu</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Cho</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Lee</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>JY</given-names></string-name>, <string-name name-style="western"><surname>Pyun</surname><given-names>WB</given-names></string-name>, <string-name name-style="western"><surname>Sung</surname><given-names>KC.</given-names></string-name></person-group><article-title>Office blood pressure range and cardiovascular events in patients with hypertension: a nationwide cohort study in South Korea</article-title>. <source>J Am Heart Assoc</source><year>2021</year>; <volume>10</volume>:<fpage>e017890</fpage>.<pub-id pub-id-type="pmid">33739126</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/JAHA.120.017890</pub-id><pub-id pub-id-type="pmcid">PMC8174356</pub-id></mixed-citation></ref><ref id="CIT0024"><label>24.</label><mixed-citation publication-type="journal"><collab>Blood Pressure Lowering Treatment Trialists&#8217; Collaboration</collab>. <article-title>Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials</article-title>. <source>Lancet</source><year>2003</year>; <volume>362</volume>:<fpage>1527</fpage>&#8211;<lpage>1535</lpage>.<pub-id pub-id-type="pmid">14615107</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0140-6736(03)14739-3</pub-id></mixed-citation></ref><ref id="CIT0025"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bae</surname><given-names>EH</given-names></string-name>, <string-name name-style="western"><surname>Lim</surname><given-names>SY</given-names></string-name>, <string-name name-style="western"><surname>Han</surname><given-names>KD</given-names></string-name>, <string-name name-style="western"><surname>Oh</surname><given-names>TR</given-names></string-name>, <string-name name-style="western"><surname>Choi</surname><given-names>HS</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>CS</given-names></string-name>, <string-name name-style="western"><surname>Ma</surname><given-names>SK</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>SW.</given-names></string-name></person-group><article-title>Association between systolic and diastolic blood pressure variability and the risk of end-stage renal disease</article-title>. <source>Hypertension</source><year>2019</year>; <volume>74</volume>:<fpage>880</fpage>&#8211;<lpage>887</lpage>.<pub-id pub-id-type="pmid">31422691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/HYPERTENSIONAHA.119.13422</pub-id><pub-id pub-id-type="pmcid">PMC6756299</pub-id></mixed-citation></ref><ref id="CIT0026"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hsu</surname><given-names>CY</given-names></string-name>, <string-name name-style="western"><surname>McCulloch</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Darbinian</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Go</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Iribarren</surname><given-names>C.</given-names></string-name></person-group><article-title>Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease</article-title>. <source>Arch Intern Med</source><year>2005</year>; <volume>165</volume>:<fpage>923</fpage>&#8211;<lpage>928</lpage>.<pub-id pub-id-type="pmid">15851645</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/archinte.165.8.923</pub-id></mixed-citation></ref><ref id="CIT0027"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tanner</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Calhoun</surname><given-names>DA</given-names></string-name>, <string-name name-style="western"><surname>Bell</surname><given-names>EK</given-names></string-name>, <string-name name-style="western"><surname>Bowling</surname><given-names>CB</given-names></string-name>, <string-name name-style="western"><surname>Guti&#233;rrez</surname><given-names>OM</given-names></string-name>, <string-name name-style="western"><surname>Irvin</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Lackland</surname><given-names>DT</given-names></string-name>, <string-name name-style="western"><surname>Oparil</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>McClellan</surname><given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Warnock</surname><given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>Muntner</surname><given-names>P.</given-names></string-name></person-group><article-title>Incident ESRD and treatment-resistant hypertension: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study</article-title>. <source>Am J Kidney Dis</source><year>2014</year>; <volume>63</volume>:<fpage>781</fpage>&#8211;<lpage>788</lpage>.<pub-id pub-id-type="pmid">24388119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.ajkd.2013.11.016</pub-id><pub-id pub-id-type="pmcid">PMC4141647</pub-id></mixed-citation></ref><ref id="CIT0028"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>De Nicola</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Gabbai</surname><given-names>FB</given-names></string-name>, <string-name name-style="western"><surname>Agarwal</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Chiodini</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Borrelli</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Bellizzi</surname><given-names>V</given-names></string-name>, <string-name name-style="western"><surname>Nappi</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Conte</surname><given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Minutolo</surname><given-names>R.</given-names></string-name></person-group><article-title>Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients</article-title>. <source>J Am Coll Cardiol</source><year>2013</year>; <volume>61</volume>:<fpage>2461</fpage>&#8211;<lpage>2467</lpage>.<pub-id pub-id-type="pmid">23623908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2012.12.061</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>